Frost & Sullivan Releases the "2026Global Peptide and Oligonucleotide Drug Industry White Paper"

2026/11/11

Peptide and oligonucleotide drugs (TIDES) have emerged as one of the faster-growing segments in innovative drug development in recent years. Driven by the commercial success of GLP-1 peptide drugs and continued breakthroughs in oligonucleotide therapies for genetic and cardiovascular diseases, the TIDES market has expanded rapidly, alongside growth in R&D pipelines and clinical programs. Meanwhile, increasing molecular complexity and rising commercialization demand have driven pharmaceutical developers' need for specialized services in process development, analytical characterization, large-scale manufacturing, and supply chain management, reinforcing the role of CDMOs across the TIDES value chain. Industry competition is shifting from capacity-driven growth toward integrated capability-based competition, with technology platforms, quality systems, manufacturing scale, and global service capabilities becoming key sources of competitive advantage. Looking ahead, continued innovation in drug design, delivery technologies, and manufacturing processes is expected to further expand the clinical applications of peptide and oligonucleotide drugs, accelerate their adoption in chronic diseases and a broader range of therapeutic areas, and drive sustained growth across the global TIDES industry.

Contact:

2026全球多肽与寡核苷酸药物行业发展白皮书.pdfDownload
Frost & Sullivan Releases the "2026Global Peptide and Oligonucleotide Drug Industry White Paper"